Literature DB >> 29260430

Effect of postoperative radiotherapy on survival in duodenal adenocarcinoma: a propensity score-adjusted analysis of Surveillance, Epidemiology, and End Results database.

Yu Jin Lim1, Kyubo Kim2.   

Abstract

PURPOSE: The use of adjuvant treatment has not been sufficiently investigated in duodenal adenocarcinoma. This study evaluated the effect of postoperative radiotherapy (PORT) on survival outcomes in this rare malignancy.
METHODS: We identified patients who were diagnosed between 2004 and 2013 in the Surveillance, Epidemiology, and End Results database. Overall survival (OS) and disease-specific survival (DSS) were analyzed before and after propensity score matching.
RESULTS: Among the 701 eligible patients, 116 (17%) underwent PORT. There were no significant differences in OS and DSS according to receipt of PORT in the unmatched population (P = 0.982 and 0.496, respectively), whereas the propensity-matched analysis showed improved OS and DSS with PORT (P = 0.053 and 0.019, respectively). No receipt of PORT was an independent poor prognostic factor in multivariate analysis of both OS (P = 0.022) and DSS (P = 0.005). The potential survival benefits of PORT were observed in subgroups of T4 stage, larger tumor size, higher lymph node ratio, and total/radical resection.
CONCLUSIONS: We provide useful insights into the therapeutic role of PORT in adenocarcinoma of the duodenum. Adjuvant strategy with PORT needs to be considered in locally advanced tumors.

Entities:  

Keywords:  Adjuvant radiotherapy; Duodenal neoplasms; Prognosis; Propensity score; Survival analysis

Mesh:

Year:  2017        PMID: 29260430     DOI: 10.1007/s10147-017-1226-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  21 in total

1.  Small bowel adenocarcinoma: understaged and undertreated?

Authors:  Michael B Nicholl; Vanita Ahuja; W Charles Conway; Vu D Vu; Myung-Shin Sim; Gagandeep Singh
Journal:  Ann Surg Oncol       Date:  2010-05-11       Impact factor: 5.344

Review 2.  Indications for propensity scores and review of their use in pharmacoepidemiology.

Authors:  Robert J Glynn; Sebastian Schneeweiss; Til Stürmer
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

3.  Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.

Authors:  Brett L Ecker; Matthew T McMillan; Jashodeep Datta; Major K Lee; Giorgos C Karakousis; Charles M Vollmer; Jeffrey A Drebin; Douglas L Fraker; Robert E Roses
Journal:  Cancer       Date:  2016-11-07       Impact factor: 6.860

4.  Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum.

Authors:  Michael J Swartz; Michael A Hughes; Deborah A Frassica; Joseph Herman; Charles J Yeo; Taylor S Riall; Keith D Lillemoe; John L Cameron; Ross C Donehower; Daniel A Laheru; Ralph H Hruban; Ross A Abrams
Journal:  Arch Surg       Date:  2007-03

5.  Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.

Authors:  Susannah Yovino; Matthew Poppe; Salma Jabbour; Vera David; Michael Garofalo; Naimesh Pandya; Richard Alexander; Nader Hanna; William F Regine
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-14       Impact factor: 7.038

6.  Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.

Authors:  Kyubo Kim; Eui Kyu Chie; Jin-Young Jang; Sun Whe Kim; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Sung W Ha
Journal:  Am J Clin Oncol       Date:  2012-12       Impact factor: 2.339

7.  Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis.

Authors:  Brett L Ecker; Matthew T McMillan; Jashodeep Datta; Ronac Mamtani; Bruce J Giantonio; Daniel T Dempsey; Douglas L Fraker; Jeffrey A Drebin; Giorgos C Karakousis; Robert E Roses
Journal:  Cancer       Date:  2015-12-30       Impact factor: 6.860

8.  What prognostic factors are important in duodenal adenocarcinoma?

Authors:  F G Bakaeen; M M Murr; M G Sarr; G B Thompson; M B Farnell; D M Nagorney; D R Farley; J A van Heerden; L M Wiersema; C D Schleck; J H Donohue
Journal:  Arch Surg       Date:  2000-06

9.  Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival.

Authors:  Timur Mitin; C Kristian Enestvedt; Ahmedin Jemal; Helmneh M Sineshaw
Journal:  J Natl Cancer Inst       Date:  2017-07-01       Impact factor: 13.506

10.  15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas.

Authors:  Edwin O Onkendi; Sarah Y Boostrom; Michael G Sarr; Michael B Farnell; David M Nagorney; John H Donohue; Michael L Kendrick; Kaye M Reid-Lombardo; William S Harmsen; Florencia G Que
Journal:  J Gastrointest Surg       Date:  2012-02-17       Impact factor: 3.452

View more
  2 in total

Review 1.  Clinical practice guidelines for duodenal cancer 2021.

Authors:  Kenji Nakagawa; Masayuki Sho; Mitsuhiro Fujishiro; Naomi Kakushima; Takahiro Horimatsu; Ken-Ichi Okada; Mikitaka Iguchi; Toshio Uraoka; Motohiko Kato; Yorimasa Yamamoto; Toru Aoyama; Takahiro Akahori; Hidetoshi Eguchi; Shingo Kanaji; Kengo Kanetaka; Shinji Kuroda; Yuichi Nagakawa; Souya Nunobe; Ryota Higuchi; Tsutomu Fujii; Hiroharu Yamashita; Suguru Yamada; Yukiya Narita; Yoshitaka Honma; Kei Muro; Tetsuo Ushiku; Yasuo Ejima; Hiroki Yamaue; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2022-10-19       Impact factor: 6.772

2.  Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma.

Authors:  Kulbir Mann; T Gilbert; S Cicconi; R Jackson; P Whelan; F Campbell; C Halloran; J Neoptolemos; P Ghaneh
Journal:  Langenbecks Arch Surg       Date:  2019-04-10       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.